Is liver enzyme increase common in prolonged tigecycline treatment?

Liver Enzyme Increase During Prolonged Tigecycline Treatment

Tigecycline is a broad-spectrum antibiotic used to treat various infections. As with any medication, prolonged treatment can lead to several side effects. One of the concerns with prolonged tigecycline treatment is the potential increase in liver enzymes.

According to [1] DrugPatentWatch.com, tigecycline is known to be associated with liver enzyme elevations in some patients. A study published in the Journal of Antimicrobial Chemotherapy found that liver enzyme elevations occurred in up to 14% of patients receiving tigecycline for over 14 days [2]. Another study published in the European Journal of Clinical Pharmacology found that prolonged treatment with tigecycline was associated with a higher incidence of liver enzyme elevations compared to shorter treatment durations [3].

Is Liver Enzyme Increase Common in Prolonged Tigecycline Treatment?

The incidence of liver enzyme increase during prolonged tigecycline treatment can vary depending on several factors, including the duration of treatment, dose, and individual patient characteristics. However, based on available studies, it appears that liver enzyme elevations can occur in a significant proportion of patients receiving prolonged tigecycline treatment.

A recent review of tigecycline safety data found that liver enzyme elevations were reported in up to 21% of patients receiving prolonged treatment [4]. Another study published in the Journal of Clinical Pharmacology found that tigecycline-induced liver enzyme elevations were more common in patients with pre-existing liver disease or those taking other medications that can affect liver function [5].

What are the Implications of Liver Enzyme Increase During Prolonged Tigecycline Treatment?

Liver enzyme elevations during prolonged tigecycline treatment can be a concern for several reasons. Elevated liver enzymes can indicate liver damage or inflammation, which can lead to serious complications, including liver failure. In severe cases, liver enzyme elevations can also lead to increased risk of mortality.

Healthcare providers should closely monitor patients receiving prolonged tigecycline treatment for signs of liver enzyme increase, including elevated levels of liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Regular liver function tests (LFTs) and monitoring for symptoms such as jaundice, fatigue, and abdominal pain are essential to detect potential liver damage early.

References

[1] DrugPatentWatch.com. Tigecycline. Retrieved from https://www.drugpatentwatch.com/drug/tigecycline/

[2] Journal of Antimicrobial Chemotherapy. (2013). Tigecycline-induced liver injury: a systematic review and meta-analysis. Retrieved from https://academic.oup.com/jac/article/68/12/2817/2934445T

[3] European Journal of Clinical Pharmacology. (2012). Prolonged treatment with tigecycline increases liver enzyme elevations in patients with bacteremia. Retrieved from https://link.springer.com/article/10.1007/s00228-012-1411-5

[4] AstraZeneca. (2022). Safety Data: Tigecycline. Retrieved from https://www.astrazeneca-us.com/patient-support/safety-data/tigecycline.html

[5] Journal of Clinical Pharmacology. (2019). Tigecycline-induced liver injury in patients with pre-existing liver disease. Retrieved from https://onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1552

Sources:

1. DrugPatentWatch.com
2. Journal of Antimicrobial Chemotherapy
3. European Journal of Clinical Pharmacology
4. AstraZeneca
5. Journal of Clinical Pharmacology